Ramoplanin is used as a treatment for multiple antibiotic-resistant Clostridium difficile infection of the gastrointestinal tract.
CAT No: 10-101-105
CAS No:76168-82-6
Synonyms/Alias:Ramoplanin; A 16686; A16686; A-16686; MD 62198; MD62198; MD-62198; MDL62198
Ramoplanin is a complex glycolipodepsipeptide antibiotic produced by Actinoplanes species, notable for its unique structure and potent activity against Gram-positive bacteria. As a nonribosomal peptide compound, it features a distinctive combination of amino acids and lipid moieties, contributing to its mechanism of action and research value. Its ability to disrupt cell wall biosynthesis at specific stages has positioned ramoplanin as an important tool for investigating bacterial physiology, antibiotic resistance mechanisms, and the development of novel antimicrobial strategies. The compound's biochemical properties make it highly relevant in microbiological research, particularly in studies focused on peptidoglycan synthesis and the molecular underpinnings of antibacterial activity.
Antibiotic mechanism research: Ramoplanin is widely utilized in studies dissecting the inhibition of cell wall biosynthesis in Gram-positive bacteria. Its mode of action involves binding to lipid II, a crucial peptidoglycan precursor, thereby preventing the transglycosylation step essential for cell wall polymerization. Researchers employ ramoplanin to elucidate the structural and functional aspects of lipid II interactions, advancing the understanding of bacterial cell wall assembly and identifying potential targets for next-generation antibiotics.
Antimicrobial resistance studies: The compound serves as a valuable agent for probing mechanisms of resistance in clinically significant pathogens such as Enterococcus and Staphylococcus species. By applying ramoplanin in laboratory models, scientists can assess the adaptive responses of bacteria, including changes in cell envelope composition, efflux pump activity, and genetic mutations that confer reduced susceptibility. These investigations contribute to the broader effort of characterizing resistance pathways and developing strategies to counteract multidrug-resistant organisms.
Peptidoglycan biosynthesis assays: Ramoplanin is frequently incorporated into in vitro assays designed to monitor peptidoglycan synthesis and modification. Its specific inhibition of lipid II-mediated polymerization enables precise measurement of enzymatic activities involved in cell wall construction. Researchers utilize it to validate assay sensitivity, benchmark the efficacy of new inhibitors, and dissect the sequential steps of peptidoglycan assembly under controlled conditions.
Antibiotic screening and validation: In the context of drug discovery, ramoplanin acts as a reference compound for benchmarking the antibacterial potency of novel agents targeting the cell wall biosynthetic pathway. Its well-characterized activity profile allows for standardized comparisons in high-throughput screening platforms, facilitating the identification of promising candidates and ensuring robust assay performance. The compound's inclusion in validation protocols supports the development of innovative therapeutics directed against resistant bacterial strains.
Structural biology and binding studies: The unique structure and binding properties of ramoplanin make it an excellent tool for structural and biophysical investigations. Researchers employ it to study the conformational dynamics of lipid II complexes using techniques such as X-ray crystallography, NMR spectroscopy, and surface plasmon resonance. These studies provide atomic-level insights into ligand-target interactions, informing the rational design of improved inhibitors and deepening the understanding of glycopeptide antibiotic mechanisms.
Ramoplanin is an actinomycetes-derived antibiotic with broad-spectrum activity against Gram-positive bacteria that has been evaluated in clinical trials for the treatment of gastrointestinal vancomycin-resistant enterococci (VRE) and Clostridium difficile infections. Recent studies have proposed that ramoplanin binds to bacterial membranes as a C2 symmetrical dimer that can sequester Lipid II, which causes inhibition of cell wall peptidoglycan biosynthesis and cell death. In this study, ramoplanin was shown to bind to anionic and zwitterionic membrane mimetics with a higher affinity for anionic membranes and to induce membrane depolarization of methicillin-susceptible Staphylococcus aureus (MSSA) ATCC 25923 at concentrations at or above the minimal bactericidal concentration (MBC). The ultrastructural effects of ramoplanin on S. aureus were also examined by transmission electron microscopy (TEM), and this showed dramatic changes to bacterial cell morphology. The correlation observed between membrane depolarization and bacterial cell viability suggests that this mechanism may contribute to the bactericidal activity of ramoplanin.
Cheng, M., Huang, J. X., Ramu, S., Butler, M. S., & Cooper, M. A. (2014). Ramoplanin at bactericidal concentrations induces bacterial membrane depolarization in Staphylococcus aureus. Antimicrobial agents and chemotherapy, 58(11), 6819-6827.
Ramoplanin, a novel antibiotic with activity against aerobic and anaerobic gram-positive bacteria, acts to prevent cell wall peptidoglycan formation by binding to a key intermediate moiety, lipid II. It has been fast-tracked by the US FDA for the prevention of enterococcal infections and the treatment of Clostridium difficile. The minimum inhibitory concentration(90s) have been < or = 1.0 microg/ml against gram-positive organisms examined. In carriers of vancomycin-resistant enterococci, a double-blind, placebo-controlled Phase II trial of two doses of ramoplanin versus placebo showed proof of concept. A second Phase II trial also demonstrated the equivalence of ramoplanin compared with vancomycin for the treatment of C. difficile colitis. The clinical value and place in therapy of ramoplanin is dependent upon the results of Phase III trials addressing its utility in suppressing carriage of target organisms in the gastrointestinal tract or in the nares.
Fulco, P., & Wenzel, R. P. (2006). Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert review of anti-infective therapy, 4(6), 939-945.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More